Zenith Health Care Ltd
Incorporated in 1993, Zenith Health
care Ltd is engaged in manufacturing
and trading of pharma products[1]
- Market Cap ₹ 14.7 Cr.
- Current Price ₹ 2.74
- High / Low ₹ 5.30 / 2.50
- Stock P/E 32.7
- Book Value ₹ 1.40
- Dividend Yield 0.00 %
- ROCE 3.12 %
- ROE 0.81 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -1.11% over past five years.
- Promoter holding is low: 28.7%
- Company has a low return on equity of 1.56% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.27 | 3.64 | 3.46 | 4.79 | 9.51 | 9.83 | 11.98 | 13.74 | 22.36 | 13.13 | 14.47 | 11.33 | 11.33 | |
| 3.54 | 3.68 | 3.69 | 4.73 | 8.95 | 9.63 | 11.43 | 13.38 | 21.91 | 13.10 | 14.23 | 11.24 | 11.00 | |
| Operating Profit | -0.27 | -0.04 | -0.23 | 0.06 | 0.56 | 0.20 | 0.55 | 0.36 | 0.45 | 0.03 | 0.24 | 0.09 | 0.33 |
| OPM % | -8.26% | -1.10% | -6.65% | 1.25% | 5.89% | 2.03% | 4.59% | 2.62% | 2.01% | 0.23% | 1.66% | 0.79% | 2.91% |
| 0.10 | 0.05 | 0.12 | 0.08 | 0.13 | 0.21 | 0.30 | 0.46 | 0.52 | 0.38 | 0.26 | 0.43 | 0.43 | |
| Interest | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Depreciation | 0.24 | 0.35 | 0.35 | 0.30 | 0.28 | 0.25 | 0.25 | 0.25 | 0.36 | 0.28 | 0.21 | 0.23 | 0.28 |
| Profit before tax | -0.41 | -0.35 | -0.47 | -0.17 | 0.40 | 0.16 | 0.59 | 0.56 | 0.60 | 0.12 | 0.28 | 0.28 | 0.48 |
| Tax % | -31.71% | -31.43% | -36.17% | -11.76% | 32.50% | 18.75% | 3.39% | 19.64% | 48.33% | 33.33% | 25.00% | 78.57% | |
| -0.27 | -0.24 | -0.31 | -0.15 | 0.27 | 0.14 | 0.57 | 0.44 | 0.31 | 0.08 | 0.20 | 0.07 | 0.45 | |
| EPS in Rs | -0.05 | -0.04 | -0.06 | -0.03 | 0.05 | 0.03 | 0.11 | 0.08 | 0.06 | 0.01 | 0.04 | 0.01 | 0.09 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | -1% |
| 3 Years: | -20% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -36% |
| 3 Years: | -42% |
| TTM: | 250% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | -17% |
| 3 Years: | -13% |
| 1 Year: | -43% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 3% |
| 3 Years: | 2% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 |
| Reserves | 0.68 | 0.48 | 0.17 | 0.02 | 0.29 | 0.43 | 1.03 | 1.47 | 1.78 | 1.86 | 1.96 | 2.03 | 2.16 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.78 | 0.60 | 1.04 | 0.74 | 1.43 | 1.14 | 2.14 | 1.92 | 4.52 | 2.02 | 2.56 | 3.48 | 3.19 | |
| Total Liabilities | 6.83 | 6.45 | 6.58 | 6.13 | 7.09 | 6.96 | 8.54 | 8.76 | 11.67 | 9.25 | 9.89 | 10.88 | 10.72 |
| 1.37 | 2.17 | 1.93 | 1.75 | 1.81 | 1.62 | 1.70 | 1.80 | 1.75 | 1.50 | 1.40 | 1.55 | 1.58 | |
| CWIP | 0.79 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 4.67 | 4.28 | 4.65 | 4.38 | 5.28 | 5.34 | 6.67 | 6.96 | 9.92 | 7.75 | 8.49 | 9.33 | 9.14 | |
| Total Assets | 6.83 | 6.45 | 6.58 | 6.13 | 7.09 | 6.96 | 8.54 | 8.76 | 11.67 | 9.25 | 9.89 | 10.88 | 10.72 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | 0.19 | 0.23 | 0.23 | 0.00 | -0.06 | 1.95 | -1.47 | 1.32 | -0.92 | 1.74 | 0.67 | |
| -0.44 | -0.14 | 0.01 | -0.12 | 0.00 | -0.05 | -0.50 | -0.19 | -0.23 | -0.03 | -1.88 | -1.09 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Cash Flow | -0.51 | 0.05 | 0.24 | 0.11 | 0.00 | -0.09 | 1.44 | -1.65 | 1.09 | -0.95 | -0.14 | -0.41 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 218.78 | 183.50 | 132.92 | 84.58 | 54.88 | 33.79 | 31.08 | 44.89 | 53.05 | 64.22 | 57.26 | 77.96 |
| Inventory Days | 192.90 | 170.89 | 297.41 | 179.91 | 102.66 | 125.86 | 99.18 | 145.11 | 104.78 | 147.45 | 86.65 | 152.87 |
| Days Payable | 132.38 | 86.27 | 177.67 | 78.95 | 82.53 | 47.61 | 84.31 | 71.22 | 37.63 | 51.11 | 38.08 | 91.59 |
| Cash Conversion Cycle | 279.29 | 268.12 | 252.65 | 185.54 | 75.01 | 112.04 | 45.95 | 118.78 | 120.21 | 160.55 | 105.84 | 139.24 |
| Working Capital Days | 296.91 | 246.68 | 208.87 | 136.40 | 82.13 | 96.17 | 48.14 | 98.02 | 50.93 | 116.76 | 60.54 | 69.59 |
| ROCE % | -6.79% | -5.71% | -8.08% | -2.93% | 7.42% | 2.79% | 9.82% | 8.61% | 8.72% | 1.81% | 3.98% | 3.12% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Domestic Sales INR Lakhs |
|
||||||||||
| Export Sales INR Lakhs |
|||||||||||
| Net Block (Property, Plant and Equipment) INR Lakhs |
|||||||||||
| Trade Receivable Turnover Ratio times |
|||||||||||
Documents
Announcements
-
Outcome Of Board Meeting
12 Feb - Approved unaudited results for quarter and nine months ended 31-Dec-2025; Q revenue Rs248.30 lakh, Q net profit Rs22.41 lakh.
-
Board Meeting Outcome for Outcome Of Board Meeting
12 Feb - Board approved unaudited Q3 and nine-month results to 31 Dec 2025: Q3 revenue Rs 248.30L, Q3 net profit Rs 22.41L.
-
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Tuesday, February 12, 2026
2 Feb - Board meeting Feb 12, 2026 to approve unaudited Q3/9M results for Dec 31, 2025; trading window closed.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
16 Jan - Submission of Decleration of RTA under Regulation 74(5) of Depositories and Participants Regulation 2018.
-
Closure of Trading Window
26 Dec 2025 - Trading window closed Jan 1, 2026 until 48 hours after unaudited Q3 results for quarter ended Dec 31, 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3]
ZHL is in the business of manufacturing pharmaceutical formulations in the forms of general and beta lactum Tablets, Capsules, Oral liquid, and Injectables. The company offers contract manufacturing of all dosage forms.
The services include purchasing of raw materials, production, packaging, and quality control, and offering solid dosage forms in General and Beta-Lactam Tablets, Capsules, Oral Liquids, and Dry Powder Oral Suspension.